作者
Nitin Jain,Michael J. Keating,Philip A. Thompson,Alessandra Ferrajoli,Jan A. Burger,Gautam Borthakur,Koichi Takahashi,Zeev Estrov,Nathan Fowler,Tapan M. Kadia,Marina Konopleva,Yesid Alvarado,Musa Yılmaz,Courtney D. DiNardo,Prithviraj Bose,Maro Ohanian,Naveen Pemmaraju,Elias Jabbour,Koji Sasaki,Rashmi Kanagal‐Shamanna,Keyur P. Patel,Jeffrey L. Jorgensen,Naveen Garg,Xuemei Wang,Katrina Sondermann,Nichole Cruz,Chongjuan Wei,Ana Ayala,William Plunkett,Hagop M. Kantarjian,Varsha Gandhi,William G. Wierda
摘要
Ibrutinib, an inhibitor of Bruton’s tyrosine kinase, and venetoclax, an inhibitor of B-cell lymphoma 2 protein, have been approved for patients with chronic lymphocytic leukemia (CLL). Preclinical investigations have indicated potential synergistic interaction of their combination.
感动归尘
Billy
嗯哼
Singularity
薰硝壤
Leon
结实大白
寻道图强
KWang
spark810
坚强的广山
kento
隐形曼青
NexusExplorer
ephore
慕青
InfoNinja
jensen
搜集达人
HEIKU
皖公网安备34019202002308
